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In response to my editorial,1 I received to my surprise four thoughtful, critical, enthusiastic, and constructive comments and reflections. My original aim was modestly 
to suggest a Theory of Change (ToC) for translating economic 
evidence, from the Disease Control Priorities (DCP) projects 
and similar sources, to better priority setting within countries. 
Davis and Walker offer a more comprehensive alternative, 
putting the client at the center. They suggest developing “a 
ToC to support progressive institutional development to 
deliver on universal health coverage [UHC].”2 They argue 
that the desired outcomes must be locally sustainable, multi-
functional, learning institutions and better governance of 
health systems for efficiency and equity. 
I could not agree more. Better priority setting is only one 
of the elements needed for stronger health systems and 
accountable governance. 
Against my view that creating institutions is the 
responsibility of countries, they see a much larger role 
for development assistance for health and ask how global 
institutions can better support national governments in low- 
and middle-income countries to establish dynamic learning 
institutions for better governance. 
Although global institutions could get their act together 
and see technical assistance as a much more important part 
of development assistance for health, I maintain that local 
capacity strengthening is a necessary first step to create 
demand for evidence and for national institutions using 
evidence for priority setting and health systems strengthening. 
In a similar vein, Isaranuwatchai and colleagues argue that 
the best way forward for the global health community is a new 
platform, a global community of practice, that can coordinate 
and integrate the many existing development initiatives – such 
as DCP, iDSI, Global Burden of Disease, Tufts’ Cost-Effective 
Analysis registry, HIV/TB/malaria modelling consortia, 
Global Health Costing Consortium, the Joint Learning 
Network, and so on – “that is driven by countries’ asks.”3 
I agree that a global community of practice is needed, and 
I would welcome such a coordinated effort. Yet, again I fail to 
see that this is a first step in a ToC and that it would put “the 
client at the center.” Unless each country, and its government 
institutions, see the need to set priorities through evidence-
based approaches, a new platform would mostly benefit 
researchers and institutions in the United States and Europe. 
Against my view that we need to go beyond cost-
effectiveness and include distributional concerns and fair 
process, they argue this new platform should take “Pride in 
Cost-Effectiveness” and that the world needs more, not less, 
cost-effectiveness analysis. They also criticize DCP for not 
using its significant global influence to challenge questionable 
global norms, especially World Health Organization’s 
(WHO’s) earlier guidance on willingness-to-pay thresholds 
that effectively said that only interventions costing more than 
three times gross domestic product per capita per quality-
adjusted life year gained or disability-adjusted life year averted 
are not cost-effective. 
I certainly agree that cost-effectiveness information is 
key to priority setting, but we need to acknowledge that 
equity impact, financial risk protection and fair process 
is as important for public acceptability. Global norms are 
changing, and I would argue that the strong empirical work 
of Claxton et al on the opportunity cost of not getting cost-
effectiveness thresholds right is gaining traction and will in 
due time change the views of key actors such as WHO and 
DCP.4,5 The data and the arguments are convincing and the 
best argument wins in the long run. 
Rachel Nugent’s reflections are especially useful for 
her honest defense of the underlying ToC of DCP3, its 
achievements, and its shortcomings.6 The main target 
audience for DCP 1-3 was, with its key message that investing 
in health has high returns, the ministries of finance and similar 
decision-makers in global health institutions. This indirect 
effect should not be underestimated and may over time create 
more demand for priority-setting evidence within global 
institutions and ministries of health. DCP3 reviewed and 
summarized high-quality health intervention effectiveness 
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and cost-effectiveness evidence and proposed essential health 
benefit packages for resource constrained countries as well as 
for countries aiming to scale up to reach UHC by 2030.7 
Yet, Nugent admits that DCP3 has not influenced national 
priority-setting to the extent that participants in DCP3 had 
hoped. Although Prabhat Jha8 cites some excellent early 
examples of the influence of DCP in India, efforts of this 
kind can and must aim to translate evidence to better priority 
setting within countries – not least in the era of Sustainable 
Development Goals and UHC. 
An important observation is that we are already in “a post-
DCP3 world.” On-line journals, global resources such as 
WHO’s Global Health Observatory, World Bank Open Data, 
and the Global Burden of Disease study make data available 
almost in real time. At a more technical level, a review of 
the usefulness of DCP3 results for Malawi’s revision of their 
essential benefit package revealed that the presentation 
of main results in book chapters and journal publications 
without a combined database covering all interventions 
limited its user-friendliness.9 In addition, the authors argue 
that disaggregated estimates of costs and effects, quantified 
uncertainty, and a systematic assessment of transferability 
from one context to another would have made this evidence 
more useful for decision-makers.
Here is clearly a role for development assistance for health 
and a global community of practice. Research is a global 
public good and should be made available for all countries 
without delay and in a user-friendly way. Neither DCP or 
WHO-Choice have yet invested enough in making their 
results available for use and critical scrutiny. 
Although Prabhat Jha, in his comment, highlights the 
achievement of DCP and argues that properly done, “DCP 
could be as important over the next 25 years as it has been 
in the past 25 years,”8 he also identifies improvements to 
the DCP approach that are required to meet the changing 
landscape of global health and to ensure relevance to 
countries. Most importantly, there is a need for a large costing 
platform, building upon WHO’s earlier analyses in different 
settings and regions. These data should be shared openly 
for unrestricted use on a globally accessible website. I agree, 
and it seems to me that all the comments converge toward a 
similar consensus. 
Jha also agrees with the need for local capacity building and 
calls for more reliance on local and direct mortality data rather 
than on models. Direct mortality data are needed to assess 
the impact of programs as modelled data cannot separate real 
changes from changing modelling assumptions. His last point 
is worth noticing. Local data are needed for local decision-
making, monitoring and evaluation. 
In summary, I find the comments extremely useful as they 
converge into a list of improvements of my initial proposed 
ToC. 
First, reformulate the long-term outcomes to not only 
include institutionalized priority setting, but also health 
systems strengthening through national, multi-functional, 
learning institutions with better governance for improved 
efficiency and equity. 
Second, identify capacity strengthening as the key input 
to create country demand for relevant evidence, systematic 
priority setting, and accountable governance of health systems 
that deliver high-quality essential UHC. 
Third, identify as another key input a global community 
of practice that can help generate the needed contextualized 
evidence, made available in a user-friendly way, with 
disaggregated information, quantified uncertainty, and a 
systematic assessment of transferability from one context to 
another. 
Fourth, assign responsibility for establishing this new 
platform. This should be seen as a key part of development 
assistance for health and would require coordination and 
attention from WHO, the World Bank/GFF, GAVI, the 
Global Fund, the United States Agency for International 
Development, and others. In my view, natural focal points are 
WHO and the World Bank as they can identify demand from 
countries, bring global institutions to the table, coordinate 
centers of expertise as providers of technical assistance, and 
facilitate work within countries. 
Fifth and finally, forget the idea that technical assistance 
equals consultants flying in and out of countries on short-
term missions. Providing technical assistance means 
building national capacity for efficient and equitable resource 
allocation, training people up to PhD level and establishing 
national academic centers of excellence, learning from 
comparable countries, and exchange of knowledge, learning, 
skills, and responsible leadership. 
With these elements in place, I believe we together could 
develop a more ambitious ToC for better priority setting, 
stronger institutions, and stronger health systems for 
achieving UHC. 
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